Treat-to-target trials: uses, interpretation and review of concepts

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

(2011) K. I. Birkeland et al.   DIABETES CARE

Emergency Hospitalizations for Adverse Drug Events in Older Americans

(2011) Daniel S. Budnitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis

(2010) D. Atar et al.   ANNALS OF THE RHEUMATIC DISEASES

Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials

(2010) Vivian Fonseca et al.   CURRENT MEDICAL RESEARCH AND OPINION

A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

(2010) S. G. Swinnen et al.   DIABETES CARE

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial

(2010) Julio Rosenstock et al.   LANCET

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

(2009) Krzysztof Strojek et al.   CURRENT MEDICAL RESEARCH AND OPINION

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETMstudy

(2009) L. Blonde et al.   DIABETES OBESITY & METABOLISM

Reconsideration of Severe Hypoglycemic Events in the Treat-to-Target Trial

(2009) George Dailey et al.   Diabetes Technology & Therapeutics

Rationale, Design, and Baseline Data of the Insulin Glargine (Lantus) Versus Insulin Detemir (Levemir) Treat-To-Target (L2T3) Study: A Multinational, Randomized Noninferiority Trial of Basal Insulin Initiation in Type 2 Diabetes

(2009) Sanne G.H.A. Swinnen et al.   Diabetes Technology & Therapeutics

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

(2009) Philip Raskin et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes

(2009) L. Fogelfeld et al.   DIABETIC MEDICINE

Implementing Treatment Guidelines for Type 2 Diabetes in Primary Care

(2009) Stephen Brunton   POSTGRADUATE MEDICINE

Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder

(2009) Stephen Brunton   POSTGRADUATE MEDICINE

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

(2008) Priscilla Hollander et al.   CLINICAL THERAPEUTICS

Biphasic Insulin Aspart 30 Three Times Daily Is More Effective Than a Twice-Daily Regimen, Without Increasing Hypoglycemia, in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Drugs

(2008) W. Yang et al.   DIABETES CARE

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

(2008) A. Liebl et al.   DIABETES OBESITY & METABOLISM

Intensification lessons with modern premixes: From clinical trial to clinical practice

(2008) Serdar Guler et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

(2008) P. C. Bartley et al.   DIABETIC MEDICINE

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETOLOGIA

An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update)

(2008) Athena Philis-Tsimikas   EXPERT OPINION ON PHARMACOTHERAPY